TP53 and prostate carcinoma: Notably, EGFR showed 1.5 (=45/29) times more interaction with up-regulated proteins in the late time points (late stimulators or terminal regulators) than in the early time points (signal initiators or early stimulators), as also seen in the enrichment of the cytoplasm in Figure 3C. TP53, which is one of the most popular proteins involved in castration-resistant prostate cancer progression, interacted with 87 proteins and was the second most important hub protein.